Feb 5 2013
Verastem, Inc., (NASDAQ: VSTM), a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced the initiation of a Phase 1/1b trial of VS-6063 in combination with paclitaxel for the treatment of advanced ovarian cancer.
VS-6063 is a potent inhibitor of focal adhesion kinase (FAK) and has demonstrated signs of clinical activity in ovarian cancer in a single agent, Phase 1 clinical trial.
"In the Phase 1 study we demonstrated that VS-6063 as a single agent was generally well tolerated, giving us optimism that this novel agent can be combined with the widely used drug paclitaxel," said Principal Investigator Howard "Skip" Burris, III, M.D., Chief Medical Officer and Executive Director, Drug Development Program, Sarah Cannon Research Institute, Nashville, TN. "Moreover, clinically meaningful disease stabilization for about 6 months was observed in 3 of 4 patients with ovarian cancer treated with a dose of VS-6063 in the range of expected activity. All of these patients had received multiple lines of prior chemotherapy, including platinum-based treatment which has been shown to preferentially select chemo-resistant cancer stem cells."
Robert Weinberg, Ph.D., Verastem co-founder and chair of the Scientific Advisory Board, has demonstrated that the FAK pathway is a critical component for the growth and survival of cancer stem cells, which are an underlying cause of tumor metastasis and recurrence.
"We believe that cancer stem cells are ultimately responsible for disease progression with ovarian and other cancers," said Dr. Joanna Horobin, Verastem Chief Medical Officer. "Through FAK inhibition, we have the potential to provide more durable clinical responses for these diseases. Verastem has advanced the science of targeting cancer stem cells so that we can now clinically evaluate the therapeutic benefit of this approach in the treatment of cancer."
The Phase 1b trial is an open-label, multicenter, dose-escalation trial of VS-6063 in combination with paclitaxel. The endpoints of the study are safety, tolerability and efficacy as determined by Response Evaluation Criteria in Solid Tumors (RECIST) and proprietary cancer stem cell biomarkers. The study will enroll up to 30 patients with ovarian cancer at three U.S. locations.
"Our unique understanding of cancer stem cell biology, coupled with our focus on execution in research and development, has allowed us to build the leading portfolio of FAK inhibitors," said Christoph Westphal, M.D., Ph.D., Verastem Chairman and Chief Executive Officer. "The VS-6063 combination study marks the first of three trials we have planned for the FAK inhibitor program in 2013, including a potentially pivotal study in mesothelioma expected to begin mid-year."
Source: Verastem, Inc.
Scientists map cancer mutations in EGFR gene, revealing drug resistance paths